BASKING RIDGE, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced today the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial. This investigatorinitiated trial, led by Dr. Anup Kasi at The University of Kansas ("KU") Cancer Center, is eval ...

Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech companies over the past three years as they seek recognition in a market that has performed 'a 180' turn since the peak of Covid vaccines interest in the sector in 2021. Risk capital has been sidelined during this politically and economically volatile period, not just in life sciences, but across microcap markets internationally. Still, for those would-be in ...

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June: BIO International Convention (June 3-6, 2024) Format: In-person Location: San Diego, California Presentation Date: Monday, June 3, 2024 Presentation Time: 2:15 p.m ...

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's lead product candidate, certepetide, is designed to enhance the effectiveness of anti-cancer drugs by activating a novel uptake pathway for better targeting of solid tumors [3] - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3] - The company anticipates announcing multiple milestones over the next two years and believes its projected capital will support operations into early 2026, including data milestones from ongoing and planned clinical trials [3] Upcoming Events - Lisata management will participate in the BIO International Convention from June 3-6, 2024, in San Diego, California, with a presentation scheduled for June 3 at 2:15 p.m. Pacific Time [1] - The company will also present at the GCFF 2024 Bio Investing Conference on June 20, 2024, at 10:00 a.m. Pacific Time [2] - David J. Mazzo, PhD, President and CEO of Lisata, will be the presenter at both events [1][2]

About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical writing. Other jobs ha ...

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the "E ...

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the "E ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants John Menditto – Vice President-Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer Kristen Buck – Executive Vice President-Research and Development and Chief Medical Officer James Nisco – Chief Accounting Officer Conference Call Participants Sara Nik – H.C. Wainwright Will Hidell – Brookline Capital Markets Pete Enderlin – MAZ Partners Steve Bro ...

Appendix Dose on days 1, 8, 15 every 28 days INTERVENTION Arm (N=20) • Nab-paclitaxel 125 mg/m2 IV • Matching certepetide Placebo IV • Gemcitabine 1000 mg/m2 IV • Matching Placebo certepetide IV 4 hours later • Timing: Enrollment completed December 2023; Earliest possible data 2024 Phase 2b randomized, doubleblind study in mPDAC testing gemcitabine + nab-paclitaxel (SoC) with two certepetide dose regimens or placebo Sponsor/Partner ▪ Qilu Pharmaceutical (funds all development in China) ▪ Primary: AEs, SAEs, ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...